Financial PerformanceThere is an agreement for additional funding with accredited investors that have committed capital of $103M, which could be used to support commercialization upon OLC approval.
Market PotentialConsidering the large market potential, a well-thought-out OLC commercial strategy, and committed funding from accredited investors, UNCY is attractive to a long-term investor.
Product DevelopmentOLC is a differentiated phosphate lowering therapy formulated using a novel nanoparticle technology, expected to achieve sustainable growth with a relatively low discontinuation rate compared to current marketed therapies.